Alcami Invests in Bruker's D8 DISCOVER HTS™ System for High-Throughput X-Ray Diffraction Screening in Pharmaceutical Formulation Development

WEERT, Netherlands and KARLSRUHE, Germany, March 3, 2017 /PRNewswire/ -- Alcami, a leading provider of custom development and manufacturing services for the pharmaceutical and biotechnology industries, and Bruker AXS, one of the world's leading suppliers of analytical X-ray solutions, today announced the delivery of Bruker's D8 DISCOVER HTS™ high-throughput X-ray Diffraction (XRD) analysis system to the Alcami site in Weert, The Netherlands.

As part of a collaboration agreement, Alcami will use the D8 DISCOVER HTS to add XRD capabilities to their laboratory service portfolio and make it available as part of their workflow-integrated solution. The D8 DISCOVER HTS combines advanced sample analysis throughput capabilities with great flexibility. This highly innovative system perfectly matches the application requirements of the pharmaceutical industry for crystallization studies, polymorph screening, structure solution, phase identification and crystallite size determination under ambient and non-ambient conditions. With its unparalleled high-throughput screening capability, the D8 DISCOVER HTS provides opportunities for optimization of the development and production of pharmaceuticals.

"We are pleased to supply our latest high-throughput screening solution, the D8 DISCOVER HTS, to Alcami," commented Dr. Lutz Bruegemann, General Manager XRD and Vice President of Bruker AXS. "High-throughput screening of well plates using X-ray diffraction is a powerful and important analysis technique for accelerating the development and improving the quality of pharmaceutical products. Alcami is a competent partner with excellent relations to many leading pharmaceutical companies. We look forward to a fruitful collaboration."

"As we continue to further invest in our people, technology, equipment and capabilities across all sites, we are pleased to partner with Bruker in bringing this unique system to our Weert, Netherlands, facility," stated Ted Dolan, Alcami's Chief Operating Officer. "The addition of the D8 DISCOVER HTS to our Center of Excellence for Solid-State Chemistry in Weert will further enhance our capabilities and expertise in this area, including our ProForm Select™ integrated service offering for solid-state chemistry and formulation development to help the pharma/biotech industry meet important milestones and maintain stability in drug development."

About D8 DISCOVER™
The D8 DISCOVER^TM is a unique multi-purpose X-ray diffractometer platform that can be configured to meet customers' analytical requirements. Due to its flexibility, the D8 DISCOVER provides top-class results in the structure analysis of all kinds of materials from powders in the pharmaceutical industry to crystalline structures in semiconductor devices. Equipped with leading technology X-ray sources, sample stages and detectors, the D8 DISCOVER maximizes the analytical benefit in research, development and process control. Via SmartCalib^TM intelligence, the D8 DISCOVER can be reconfigured without time consuming alignment, leaving more time for data collection.

About Bruker Corporation (NASDAQ: BRKR)
For more than 50 years, Bruker has enabled scientists to make breakthrough discoveries and develop new applications that improve the quality of human life.  Bruker's high-performance scientific research instruments and high-value analytical and diagnostic solutions enable customers to explore life and materials at molecular, cellular and microscopic levels. 

In close cooperation with our customers, Bruker is enabling innovation, productivity and customer success in life science molecular research, in applied and pharma applications, in microscopy, nano-analysis and industrial applications, as well as in cell biology, preclinical imaging, clinical research, microbiology and molecular diagnostics.  For more information, visit www.bruker.com.

About Alcami
Alcami is a world-class supplier of comprehensive pharmaceutical development and manufacturing services. With seven sites across the globe, our combined capabilities include API development and manufacturing, solid-state chemistry, formulation development, analytical development and testing services, clinical and commercial finished dosage form manufacturing (oral solid dose and parenteral), packaging, and stability services. For more information, visit www.alcaminow.com.

Logo - http://mma.prnewswire.com/media/344471/alcami_logo_4c_h_logo_Logo.jpg

SOURCE Alcami